Aims: The intermittent administration of chemotherapy is a means of preserving patients' quality of life (QL). The aim of this study was to verify whether the intermittent administration of docetaxel (DOC) improves the patients' QL. Patients & methods: All patients received DOC 70 mg/m every 3 weeks for eight cycles. The patients were randomized to receive DOC continuously or with a fixed 3-month interval after the first four DOC courses. Results: The study involved 148 patients. There was no difference in QL between the groups receiving intermittent or continuous treatment. Intermittence had no detrimental effects on disease control. Conclusion: Although feasible and not detrimental, our results showed that true intermittent chemotherapy in metastatic castration-resistant prostate cancer patients failed to improve the patients' QL.

Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients / Caffo, O.; Lo Re, G.; Sava, T.; Buti, S.; Sacco, C.; Basso, U.; Zustovich, F.; Lodde, M.; Perin, A.; Facchini, G.; Veccia, A.; Maines, F.; Barile, C.; Fratino, L.; Gernone, A.; De Vivo, R.; Pappagallo, G. L.; Galligioni, E.. - In: FUTURE ONCOLOGY. - ISSN 1479-6694. - 11:6(2015), pp. 965-973. [10.2217/fon.14.284]

Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients

Buti S.;
2015

Abstract

Aims: The intermittent administration of chemotherapy is a means of preserving patients' quality of life (QL). The aim of this study was to verify whether the intermittent administration of docetaxel (DOC) improves the patients' QL. Patients & methods: All patients received DOC 70 mg/m every 3 weeks for eight cycles. The patients were randomized to receive DOC continuously or with a fixed 3-month interval after the first four DOC courses. Results: The study involved 148 patients. There was no difference in QL between the groups receiving intermittent or continuous treatment. Intermittence had no detrimental effects on disease control. Conclusion: Although feasible and not detrimental, our results showed that true intermittent chemotherapy in metastatic castration-resistant prostate cancer patients failed to improve the patients' QL.
Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients / Caffo, O.; Lo Re, G.; Sava, T.; Buti, S.; Sacco, C.; Basso, U.; Zustovich, F.; Lodde, M.; Perin, A.; Facchini, G.; Veccia, A.; Maines, F.; Barile, C.; Fratino, L.; Gernone, A.; De Vivo, R.; Pappagallo, G. L.; Galligioni, E.. - In: FUTURE ONCOLOGY. - ISSN 1479-6694. - 11:6(2015), pp. 965-973. [10.2217/fon.14.284]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2914339
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 7
social impact